All In Biotech

Drug Trial Radar · NCT03416179

A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia

A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA

Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Apr 20, 2018

Primary completion

Jun 5, 2020

Study completion Jan 17, 2022

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Glasdegib is being studied in combination with azacitidine for the treatment of adult patients with previously untreated acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy (Non-intensive AML population). Glasdegib is being studied in combination with cytarabine and daunorubicin for the treatment of adult patients with previously untreated acute myeloid leukemia (Intensive AML population).

Conditions

  • Leukemia, Myeloid, Acute

Interventions

  • glasdegibDrug

    Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first. Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.

  • daunorubicin + cytarabineDrug

    '7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days). If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');

  • azacitidineDrug

    Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.

  • PlaceboDrug

    Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first. Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.

  • PlaceboDrug

    Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.

  • glasdegibDrug

    Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.

  • cytarabineDrug

    Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.

  • HSCTProcedure

    If required, and done per standard of care post Induction(s).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intensive Study: Overall Survival (OS)Time frame: Baseline up to 25 months
  2. Non-intensive Study: Overall Survival (OS)Time frame: Baseline up to 25 months

Locations

149 sites in 22 countries. Site status is shown where the registry gives one.

  • UCLA Department of Medicine

    Los Angeles, California

  • UCLA Drug Information/Investigational Drugs

    Los Angeles, California

  • UCLA Hematology/Oncology Clinic

    Los Angeles, California

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • UCLA Hematology/Oncology - Westlake Village

    Westlake Village, California

  • Augusta University Medical Center

    Augusta, Georgia

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Tufts Medical Center Investigational Drug Pharmacy

    Boston, Massachusetts

  • Tufts Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • MidAmerica Division, Inc., c/o Research Medical Center

    Kansas City, Missouri

  • Northwell Health/Monter Cancer Center

    Lake Success, New York

  • North Shore University Hospital

    Manhasset, New York

  • Long Island Jewish Medical Center

    New Hyde Park, New York

  • University of Rochester Medical Center

    Rochester, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • OHSU Center for Health and Healing

    Portland, Oregon

  • Oregon Health & Science University

    Portland, Oregon

  • Centennial Medical Center

    Nashville, Tennessee

  • TriStar Bone Marrow Transplant

    Nashville, Tennessee

  • Baylor University Medical Center

    Dallas, Texas

  • Blood Cancer and Stem Cell Transplant Clinic

    San Antonio, Texas

  • Methodist Healthcare System of San Antonio

    San Antonio, Texas

  • Swedish Cancer Institute

    Seattle, Washington

  • Swedish Medical Center

    Seattle, Washington

  • St Vincent's Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU

    Salzburg, Austria

  • Uniklinikum Salzburg, Landeskrankenhaus Salzburg

    Salzburg, Austria

  • Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel

    Vienna, Austria

  • AZ Sint-Jan Brugge-Oostende av

    Bruges, Belgium

  • Universitaire Ziekenhuizen Brussel (UZ Brussel)

    Brussels, Belgium

  • Universitaire Ziekenhuizen Brussel

    Brussels, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.